COLLPLANT BIOTECH. IS-01 (F:CPT) — Market Cap & Net Worth
Market Cap & Net Worth: COLLPLANT BIOTECH. IS-01 (CPT)
COLLPLANT BIOTECH. IS-01 (F:CPT) has a market capitalization of $4.34 Million (€3.71 Million) as of August 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #28805 globally and #2483 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying COLLPLANT BIOTECH. IS-01's stock price €0.27 by its total outstanding shares 14415128 (14.42 Million). See COLLPLANT BIOTECH. IS-01 capex to cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
COLLPLANT BIOTECH. IS-01 Market Cap History: 2026 to 2026
COLLPLANT BIOTECH. IS-01's market capitalization history from 2026 to 2026. Data shows growth from $4.48 Million to $4.48 Million (0.00% CAGR).
COLLPLANT BIOTECH. IS-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how COLLPLANT BIOTECH. IS-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CPT by Market Capitalization
Companies near COLLPLANT BIOTECH. IS-01 in the global market cap rankings as of August 5, 2026.
Key companies related to COLLPLANT BIOTECH. IS-01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
COLLPLANT BIOTECH. IS-01 Historical Marketcap From 2026 to 2026
Between 2026 and today, COLLPLANT BIOTECH. IS-01's market cap moved from $4.48 Million to $ 4.48 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €4.48 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of COLLPLANT BIOTECH. IS-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.34 Million USD |
| MoneyControl | $4.34 Million USD |
| MarketWatch | $4.34 Million USD |
| marketcap.company | $4.34 Million USD |
| Reuters | $4.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About COLLPLANT BIOTECH. IS-01
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal a… Read more